Your product works.
Current clients are happy.
You should have more market share
and revenue should be increasing,
but your growth has stalled.
Somewhere between the pipeline and the P&L,
something is leaking, or the internal engine hasn't
kept pace with where the market is now.
The Revenue Plateau...
-
Stuck between $1M - $100M+
-
No clear path to breakthrough
-
Next level requires a different commercial approach
Pricing Leakage...
-
Discounting is habit, not strategy
-
Protecting volume while quietly eroding profitability
-
Costs are up, and you're eating them
Random Acts of Selling...
-
Sale territory coverage doesn't map to where margin lives
-
Reps chasing volume, but not value, nor efficiency
-
Commercial strategy built for the past, not now, not the future
A Pipeline Fiction...
-
CRM looks active, but the forecasts don't add up
-
Reps update fields, not advancing deals
-
Production/supply chain can't tell which opportunities are real.
Why Choose C-EMG?
3.6x
Revenue
Growth
Example: $28M → $102M
revenue in < 3 years.
​
Multiple successful commercial rebuilds
9 Major
Contracts
Key enterprise agreements > $25M in annual contract value.
Built the deal framework, closed the deal, then made sure it worked.
+11% Global Sales Lift
… with 9% product profitability improvement.
Coverage redesign and pricing discipline delivered simultaneously.
4 Product Launches
Global product launches with recognized revenue in under 6 months.
Included US - EU manufacturing integration.
Proven Results in Regulated B2B​​​
These wins come from actively building systems
in real life, not from writing strategy decks
Market and key client segmentation modeling, coverage design, enterprise deal framework, and partnership playbook used
to achieve these outcomes are customized and deployed in
every CXO engagement.
​
Who Benefits The Most From
What We Do...
The Ideal Fit...
Regulated manufacturing, or suppliers to regulated manufacturing
companies - typically between $500k - $250M - industrial sectors where commercial excellence and operational rigor are both critical
​​
​Pharma Manufacturing and/or Distribution, Medical Devices, Biotech, Diagnostics, Healthcare Services, Food & Beverage, (Regulated) Industrial Manufacturing, Energy, Sustainability​
​
Typical engagement triggers:
​
-
Revenue plateau with no clear path through it
​
-
AI on the board agenda but no internal owner
​
-
Leadership gap during transition or post-acquisition
​
-
Product portfolio aging with no innovation roadmap
​
-
International expansion into the Americas, EMEA, APAC
​